Mohit Bansal
Stock Analyst at Wells Fargo
(4.28)
# 418
Out of 5,115 analysts
187
Total ratings
69.44%
Success rate
9.58%
Average return
Main Sectors:
Stocks Rated by Mohit Bansal
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IRWD Ironwood Pharmaceuticals | Maintains: Equal-Weight | $3 → $5 | $4.89 | +2.25% | 6 | Jan 5, 2026 | |
| MIST Milestone Pharmaceuticals | Maintains: Overweight | $4 → $8 | $1.91 | +318.85% | 2 | Dec 16, 2025 | |
| LLY Eli Lilly and Company | Maintains: Overweight | $1,100 → $1,200 | $1,037.15 | +15.70% | 18 | Dec 10, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Equal-Weight | $53 → $55 | $55.05 | -0.09% | 10 | Dec 10, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Overweight | $460 → $515 | $469.90 | +9.60% | 12 | Dec 10, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Equal-Weight | $700 → $745 | $741.45 | +0.48% | 21 | Dec 10, 2025 | |
| GILD Gilead Sciences | Maintains: Overweight | $145 → $150 | $141.95 | +5.67% | 13 | Dec 10, 2025 | |
| BIIB Biogen | Maintains: Equal-Weight | $155 → $190 | $179.89 | +5.62% | 15 | Dec 10, 2025 | |
| AMGN Amgen | Maintains: Equal-Weight | $300 → $325 | $341.88 | -4.94% | 12 | Dec 10, 2025 | |
| MRK Merck & Co. | Upgrades: Overweight | $90 → $125 | $110.27 | +13.36% | 12 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $170 → $235 | $164.49 | +42.87% | 3 | Nov 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $50 → $55 | $30.89 | +78.05% | 3 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $90 → $70 | $56.54 | +23.81% | 6 | Oct 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $240 → $260 | $223.01 | +16.59% | 10 | Sep 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $27 → $35 | $31.09 | +12.58% | 5 | Sep 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $170 → $150 | $113.75 | +31.87% | 2 | Aug 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $50 → $47 | $41.01 | +14.61% | 2 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $60 → $65 | $71.71 | -9.36% | 7 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $14.48 | +107.18% | 1 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $70 | $43.26 | +61.81% | 1 | Nov 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $28 → $30 | $26.44 | +13.46% | 10 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $140 → $170 | $136.06 | +24.94% | 7 | Apr 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $1,875 | $29.27 | +6,305.88% | 1 | Mar 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $36 | $3.87 | +830.23% | 1 | Nov 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $19 | $10.92 | +73.99% | 3 | Apr 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $30 → $60 | $1.16 | +5,072.41% | 4 | Dec 3, 2019 |
Ironwood Pharmaceuticals
Jan 5, 2026
Maintains: Equal-Weight
Price Target: $3 → $5
Current: $4.89
Upside: +2.25%
Milestone Pharmaceuticals
Dec 16, 2025
Maintains: Overweight
Price Target: $4 → $8
Current: $1.91
Upside: +318.85%
Eli Lilly and Company
Dec 10, 2025
Maintains: Overweight
Price Target: $1,100 → $1,200
Current: $1,037.15
Upside: +15.70%
Bristol-Myers Squibb Company
Dec 10, 2025
Maintains: Equal-Weight
Price Target: $53 → $55
Current: $55.05
Upside: -0.09%
Vertex Pharmaceuticals
Dec 10, 2025
Maintains: Overweight
Price Target: $460 → $515
Current: $469.90
Upside: +9.60%
Regeneron Pharmaceuticals
Dec 10, 2025
Maintains: Equal-Weight
Price Target: $700 → $745
Current: $741.45
Upside: +0.48%
Gilead Sciences
Dec 10, 2025
Maintains: Overweight
Price Target: $145 → $150
Current: $141.95
Upside: +5.67%
Biogen
Dec 10, 2025
Maintains: Equal-Weight
Price Target: $155 → $190
Current: $179.89
Upside: +5.62%
Amgen
Dec 10, 2025
Maintains: Equal-Weight
Price Target: $300 → $325
Current: $341.88
Upside: -4.94%
Merck & Co.
Nov 24, 2025
Upgrades: Overweight
Price Target: $90 → $125
Current: $110.27
Upside: +13.36%
Nov 18, 2025
Maintains: Overweight
Price Target: $170 → $235
Current: $164.49
Upside: +42.87%
Nov 11, 2025
Maintains: Overweight
Price Target: $50 → $55
Current: $30.89
Upside: +78.05%
Oct 28, 2025
Maintains: Overweight
Price Target: $90 → $70
Current: $56.54
Upside: +23.81%
Sep 12, 2025
Maintains: Overweight
Price Target: $240 → $260
Current: $223.01
Upside: +16.59%
Sep 11, 2025
Maintains: Overweight
Price Target: $27 → $35
Current: $31.09
Upside: +12.58%
Aug 5, 2025
Maintains: Overweight
Price Target: $170 → $150
Current: $113.75
Upside: +31.87%
May 13, 2025
Maintains: Overweight
Price Target: $50 → $47
Current: $41.01
Upside: +14.61%
May 7, 2025
Maintains: Equal-Weight
Price Target: $60 → $65
Current: $71.71
Upside: -9.36%
Dec 11, 2024
Initiates: Overweight
Price Target: $30
Current: $14.48
Upside: +107.18%
Nov 21, 2024
Initiates: Overweight
Price Target: $70
Current: $43.26
Upside: +61.81%
Jul 31, 2024
Maintains: Equal-Weight
Price Target: $28 → $30
Current: $26.44
Upside: +13.46%
Apr 24, 2024
Upgrades: Overweight
Price Target: $140 → $170
Current: $136.06
Upside: +24.94%
Mar 26, 2021
Initiates: Buy
Price Target: $1,875
Current: $29.27
Upside: +6,305.88%
Nov 3, 2020
Initiates: Buy
Price Target: $36
Current: $3.87
Upside: +830.23%
Apr 30, 2020
Maintains: Buy
Price Target: $16 → $19
Current: $10.92
Upside: +73.99%
Dec 3, 2019
Upgrades: Neutral
Price Target: $30 → $60
Current: $1.16
Upside: +5,072.41%